

CONFIDENTIAL INFORMATION



TO/FROM	DATE:	02/29/2024
	RE:	Important drug therapy information from Prime Therapeutics
	ATTN:	LINDSEY BARTON NPI: 1215285879
	PHONE:	(334) 568-2120
	FAX:	(334) 244-3396
	FROM:	Prime Therapeutics
	MESSAGE:	Prime Therapeutics' GuidedHealth program offers valuable insights that may enhance the care you provide to your patients. Many of these opportunities are important patient outcome measures for the Centers for Medicare and Medicaid Services (CMS). Please use the following information to supplement your patient records and evaluate whether a change in therapy or discussion with your patient is appropriate. Please communicate any changes directly to your patient and your patient's pharmacy. If you feel the recommendation(s) does not apply, kindly disregard this message.

Number of pages including cover: 2

Confidential/Protected Health Information (PHI) Provider Follow-Up

If you are the provider and the enclosed patient information is correct – NO FURTHER ACTION IS REQUIRED.

Fax and address information for prescribers is taken from the NPPES NPI Registry Primary Practice Address. Prescribers are responsible to make all contact updates directly at <https://nppes.cms.hhs.gov/#/>.

If you have received a profile for a patient for whom you are not the prescriber and/or have not provided care, please visit www.primetherapeutics.com/ProviderFollowUp to answer a few short questions about the incorrect patient information. Please destroy this message to protect patient confidentiality.

Health Guide Survey

If you would like to provide feedback to help us improve our communications with you, please visit this website to complete a short survey: <https://www.primetherapeutics.com/GHSurvey>. To protect patient confidentiality, please do not include any patient identifiable information in this survey.

Insurer Code: AL3100 BCBSAL

Batch ID: 3437dbd04e

GuidedHealth® is a registered trademark of Prime Therapeutics LLC (Prime), a pharmacy benefit management company. Prime Therapeutics LLC (Prime) is an independent pharmacy benefit management company dedicated to providing innovative, clinically based, cost-effective pharmacy solutions.

Msg ID: 3437dbd04e5840fea2399ef76d4ce5de

CONFIDENTIAL INFORMATION

Health Guide

Considerations to help your patients
improve their health

02/28/2024

Prepared for LINDSEY BARTON,

A recent review of pharmacy claims has identified the following drug therapy opportunity for your patient:

KAYLA FREE

DOB: 10/21/1999

Member ID #: 85412439602

Prime Therapeutics

AL3100 BCBSAL

Bottom line: Non-adherent to asthma medication

Action requested: Evaluate drug refill patterns

The Adherence asthma program identifies patients whose proportion of days covered (PDC) is less than 80%. This patient's PDC is 61% over the previous 365 days. Common reasons for non-adherence may include: side effects, affordability, or changes in the drug regimen. Please provide a new prescription if the regimen has changed, and/or discuss the importance of adherence and ways to address barriers with your patient.

The chart below details the patient's pharmacy claims used to identify the above drug therapy opportunity. The medication list is current as of 02/28/2024

Date Filled	Drug Name/Strength	Dispensed Quantity	Days Supply	Pharmacy Name	Pharmacy Phone	Prescriber of Record Name	Prescriber Phone
20231005	MONTELUKAST TAB 10MG	90	90	CVS PHARMACY #04838	(334) 365-0661	LINDSEY BARTON	(334) 568-2120

IMPORTANT WARNING: We identify prescribers based on the National Provider Identifier (NPI) submitted by pharmacies on the prescription drug claims. Due to the potential for claim submission errors, please validate the above information. This information is not intended to replace your clinical judgement and is being provided to you for purposes of quality, care coordination, and other health care operations as permitted by the Health Insurance Portability and Accountability Act (HIPAA). Only a physician in direct consultation with the patient may determine whether to pursue drug therapy opportunities.

3/1/24
L. Barton, CLP